Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.756
-0.058 (-7.09%)
Nov 21, 2024, 11:59 AM EST - Market open
Seres Therapeutics Employees
Seres Therapeutics had 233 employees as of December 31, 2023. The number of employees decreased by 198 or -45.94% compared to the previous year.
Employees
233
Change (1Y)
-198
Growth (1Y)
-45.94%
Revenue / Employee
$542,167
Profits / Employee
-$109,335
Market Cap
128.65M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
American Well | 1,104 |
TELA Bio | 227 |
Protalix BioTherapeutics | 208 |
Rani Therapeutics Holdings | 140 |
Vigil Neuroscience | 69 |
InflaRx | 62 |
Milestone Pharmaceuticals | 47 |
Journey Medical | 41 |
MCRB News
- 8 days ago - Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - GlobeNewsWire
- 7 weeks ago - Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - GlobeNewsWire
- 7 weeks ago - Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé - Business Wire
- 7 weeks ago - Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 - GlobeNewsWire
- 2 months ago - Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade - Seeking Alpha
- 2 months ago - Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - GlobeNewsWire